Traumatology

4 university colleges in Denmark join forces to enhance on-site and remote education for radiographers with Sectra Education Portal

Retrieved on: 
Thursday, April 25, 2024
International, Learning, UNC, Elective surgery, University, University college, Medical education, Anatomy, Traumatology, Radiology, Faculty, Diagnosis, Health, UCL, Student, Nursing

LINKÖPING, Sweden, April 25, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark.

Key Points: 
  • LINKÖPING, Sweden, April 25, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark.
  • The four university colleges adopting Sectra's platform for medical education are University College Nordjylland (UNC), University College (UCL), Københavns Professionshøjskole (KP) and Professionshøjskolen Absalon.
  • By transferring to the education portal, we look forward to greatly enhancing the learning experience for our radiographer students.
  • The Sectra Education Portal is a subscription-based Software-as-a-Service solution that provides visualization tools and content at the university, at home or at the hospital.

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

University of Saarland chooses Sectra Education Portal to bridge the gap to clinical reality for radiographer students

Retrieved on: 
Monday, February 19, 2024
International, Medical school, Student, Research, Education, Medical education, Radiology, UDS, Learning, Traumatology, Elective surgery, University, Saarland University, Health, Teaching, Anatomy, Diagnosis, Faculty, UKS, Nursing

LINKÖPING, Sweden, Feb. 19, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide the University of Saarland with its platform for medical education — Sectra Education Portal.

Key Points: 
  • LINKÖPING, Sweden, Feb. 19, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide the University of Saarland with its platform for medical education — Sectra Education Portal.
  • By adding Sectra's solution for medical education to their existing Sectra enterprise imaging solution, they are bridging the gap between education and the clinical reality.
  • Saarland University (UdS) is a public research university organized into six faculties covering all major scientific fields.
  • One of these being the Faculty of Medicine, which is located together with Saarland University Hospital (UKS) in Homburg/Saar in Germany.

Global Veterinary Computed Tomography Scanner Market Analysis & Forecast 2024-2034, Featuring Epica Animal Health, Asto CT, Hallmarq Veterinary Imaging, Xoran Technologies & Isabelle Vets

Retrieved on: 
Monday, February 12, 2024
Pet, Livestock, USD, Zoonosis, Animal, Injury, Dog, Traumatology, Prevalence, Health, Pithing, Cat, CBCT, Fluoroscopy, Research, Cancer, Medical imaging

DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Global Veterinary Computed Tomography Scanner Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Global Veterinary Computed Tomography Scanner Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • Rise in technologically advanced product launches for treating animal diseases is predicted to boost the market growth during the forecast period.
  • The veterinary computed tomography scanner is expected to see increased demand, driven by a preference among pet practitioners for its superior diagnostic capabilities.
  • By end-user, veterinary hospitals was the highest revenue-grossing segment in the global veterinary computed tomography scanner market in 2023 owing to growing focus on development of new technologies, increasing technological advancements, and rising initiatives by market players.

More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment

Retrieved on: 
Saturday, January 13, 2024
Education, Innovation system, AAP, Patient, Clinical trial, Medicine, Traumatology, BMBF, Trial of the century, Health, Pharmaceutical industry

Further successful compassionate use cases make aap optimistic that corresponding results will also be achieved in the human clinical trial.

Key Points: 
  • Further successful compassionate use cases make aap optimistic that corresponding results will also be achieved in the human clinical trial.
  • Depending on the human clinical trial and the regulatory authorities, aap expects the first market launch of its new technology in three years.
  • The human clinical study is funded by the Federal Ministry of Education and Research ("BMBF").
  • According to the BMBF, projects on the topic of "Transferring medical technology solutions to patient care - proving clinical evidence without delay" are being funded.

A.D.A.M. and the Masovian Regional Hospital Launch Facility Construction to Treat the Victims of Russia's War on Ukraine

Retrieved on: 
Monday, December 11, 2023
POC, GMP, Regional hospital, Patient, JANA, Traumatology, Rehabilitation, Neurosurgery, Trauma, Partnership, 3D, Hospital, Medical device, 3D printing

(Masovian Regional Hospital) signed a Cooperation Agreement to establish an A.D.A.M.

Key Points: 
  • (Masovian Regional Hospital) signed a Cooperation Agreement to establish an A.D.A.M.
  • Point-of-Care (POC) facility in Poland and to utilize the Medical Device Production System (MDPS) to treat patients who require bone implants.
  • The signing took place on the premises of the Masovian Regional Hospital in Siedlce, Poland.
  • investor, states: "Poland has also been instrumental in supporting humanitarian efforts stemming from the Russian war on Ukraine.

Renowned Addiction Expert and Traumatologist Releases New Book on Addiction, Trauma, and Families

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Traumatology, Amazon, Addiction, Trauma, Family therapy, LPC, Literature

DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology. This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.

Key Points: 
  • Michael F. Barnes, Ph.D, LAC, LPC recently released a book written for families struggling with addiction and trauma called, "When The Solution Becomes The Problem: Helping Families Struggling with Addiction and Trauma".
  • DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology.
  • This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.
  • The book can be purchased on Amazon or on Dr. Barnes' website: www.drmikebarnes.com .

EQS-News: Visible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative strength of silver coating technology

Retrieved on: 
Tuesday, November 7, 2023
Trial of the century, Clinical trial, Traumatology, Titanium, Health, Federal Ministry of Education and Research (Germany), German, BMBF, Medicine, AAP, Silver, The Company, EUR, Guideline, Education, Patient, Root analogue dental implant, Acceleration, Pharmaceutical industry, Research

aap Implantate AG ("aap" or the "Company") announces that, at aap's request, the German Federal Ministry of Education and Research (BMBF) has increased the overall funding framework for the conduct of the human clinical trial for the intended market approval of its silver coating technology by approximately EUR 0.4 million. In addition to the funding of up to EUR 2.7 million already committed by the BMBF in 2019, this now results in a funding framework of up to EUR 3.1 million over the entire duration of the study. The BMBF funding underscores the innovative and strategic nature of aap's silver coating technology and its potential to significantly relieve healthcare systems at the cost level.
In the human clinical trial, which was able to enroll the first patient according to the adapted study protocol in May, a visible acceleration in patient recruitment was achieved. By mid-October, more than 60 patients were enrolled in the study as planned. Overall, the study has been very successful to date. This is reflected, among other things, in the significantly lower number of incidents of predefined, product-dependent adverse events than originally assumed in the study planning. If this trend continues, the necessary number of patients to be included would be reduced in order to make the statistical statements. Depending on patient volume and possible events as mentioned above, aap expects to complete patient recruitment in the course of 2024.
With its groundbreaking surface modification technology, in which elemental silver is incorporated into the titanium surface in an extremely low but highly effective concentration, aap is aiming for a unique selling proposition that effectively counters increasing antibiotic resistance in medicine and has the potential to become the gold standard in traumatology. Depending on the human clinical trial and the regulatory authorities, aap expects the first market launch of the new technology in 3 years.
The execution of the clinical study is funded by the German Federal Ministry of Education and Research ("BMBF"). The grant awarded to the company (grant numbers 13GW0313A+B, 13GW0449A+B) is part of the BMBF's (= grantor) field of action "Healthcare Industry in the Health Research Framework Program". According to the BMBF, projects on the topic of "Transferring medical technology solutions into patient care - proving clinical evidence without delay" are being funded. For further information, please refer to the corresponding guideline on the BMBF website: https://www.bmbf.de/foerderungen/bekanntmachung-1376.html.--------------...
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges -

Key Points: 
  • Visible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative strength of silver coating technology
    The issuer is solely responsible for the content of this announcement.
  • The BMBF funding underscores the innovative and strategic nature of aap's silver coating technology and its potential to significantly relieve healthcare systems at the cost level.
  • In the human clinical trial, which was able to enroll the first patient according to the adapted study protocol in May, a visible acceleration in patient recruitment was achieved.
  • Depending on the human clinical trial and the regulatory authorities, aap expects the first market launch of the new technology in 3 years.

BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds

Retrieved on: 
Monday, October 30, 2023
FDM, Medical device regulation, Medtech, MDR, Bone, Injury, CT, Workflow, Orthopedic surgery, ISO, Sterilization, 3D printing, Medical device, Traumatology

The presentation titled "Semi-automated workflow for the design and fabrication of 3D-printed patient-specific resorbable scaffolds for the treatment of large segmental bone defects while complying with MDR regulations" outlined the potential of BellaSeno´s novel resorbable scaffolds for curing large segmental bone defects (> 5cm size).

Key Points: 
  • The presentation titled "Semi-automated workflow for the design and fabrication of 3D-printed patient-specific resorbable scaffolds for the treatment of large segmental bone defects while complying with MDR regulations" outlined the potential of BellaSeno´s novel resorbable scaffolds for curing large segmental bone defects (> 5cm size).
  • The scaffold is needed to hold the autologous bone graft in position for optimal vascularization and bone healing.
  • Scaffolds made by additive manufacturing from bioresorbable polymers represents a highly attractive opportunity to produce such patient-specific open-pore scaffolds.
  • This results in a new generation of high-performance bone scaffolds which are well suited for the biological reconstruction of large bone defects."